{"version":"1.0","type":"link","title":"Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma.","author_name":"Armand P 외","author_url":"https://prs-insight.online/author/Armand%20P","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/171365","thumbnail_width":1200,"thumbnail_height":630}